导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.11% | 1469/4773 |
| 近一周 | -1.27% | 1926/5465 |
| 近一月 | -8.59% | 4996/5421 |
| 近一季 | -18.94% | 4840/5231 |
| 近半年 | -0.61% | 1529/4920 |
| 近一年 | 8.31% | 1343/4394 |
| 近两年 | 120.36% | 428/2954 |
| 近三年 | 71.88% | 324/2253 |
| 成立以来 | 99.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.59% 1867/4961 |
36.75% 887/5312 |
- - |
- - |
| 2025 | 51.46% 436/4813 |
-1.49% 2677/3635 |
3.28% 1067/4076 |
50.16% 318/4524 |
-0.87% 2691/4813 |
| 2024 | 15.15% 959/3463 |
-3.89% 1576/2808 |
-6.32% 1909/3014 |
29.42% 160/3129 |
-1.18% 1617/3463 |
| 2023 | -18.79% 1827/2656 |
2.13% 1439/2280 |
-7.12% 1780/2385 |
-9.49% 1836/2515 |
-5.41% 1348/2655 |
| 2022 | -29.10% 1588/2207 |
-19.93% 1508/1919 |
5.97% 802/2016 |
-18.43% 1707/2113 |
2.44% 938/2208 |
| 2021 | 11.77% 396/1822 |
-7.05% 1053/1255 |
25.95% 80/1330 |
-6.55% 955/1466 |
2.16% 675/1822 |
| 2020 | 64.25% 100/1250 |
3.68% 110/1028 |
30.41% 56/1067 |
5.57% 909/1164 |
15.07% 235/1184 |
| 2019 | 44.73% 165/1092 |
35.22% 98/754 |
-10.18% 721/804 |
7.71% 79/850 |
10.63% 111/918 |
| 2018 | -27.59% 425/834 |
- - |
- - |
- - |
-11.15% 255/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 工银瑞信创业板ETF VS. 长安沪深300非周期A(740101) |